VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202
VYNE Therapeutics Inc., a Delaware-based biopharmaceutical company, recently disclosed significant developments in its clinical trials concerning VYN202, a novel BD2-Selective BET Inhibitor. The company issued a press release on December 23, 2024, highlighting positive top-line Phase 1a MAD (Multiple Ascending Dose) data for the experimental compound. The Phase 1a trial results indicated that VYN202 exhibited […]
More Stories
FY2026 Earnings Estimate for WaFd Issued By DA Davidson
WaFd, Inc (NASDAQ:WAFD – Free Report) – Stock analysts at DA Davidson issued their FY2026 EPS estimates for shares of...
Q1 Earnings Forecast for SentinelOne Issued By KeyCorp
SentinelOne, Inc. (NYSE:S – Free Report) – Research analysts at KeyCorp issued their Q1 2026 earnings estimates for shares of...
Research Analysts Set Expectations for CMC FY2027 Earnings
Commercial Metals (NYSE:CMC – Free Report) – Analysts at Zacks Research lowered their FY2027 earnings per share estimates for Commercial...
Zacks Research Issues Pessimistic Outlook for ERIC Earnings
Telefonaktiebolaget LM Ericsson (publ) (NASDAQ:ERIC – Free Report) – Equities researchers at Zacks Research decreased their Q4 2025 earnings per...
B. Riley Has Optimistic Outlook of CVE:HIV FY2025 Earnings
HIVE Blockchain Technologies Ltd. (CVE:HIV – Free Report) – Analysts at B. Riley raised their FY2025 earnings estimates for HIVE...
Autozi Internet Technology (Global) (NASDAQ:AZI) versus Driven Brands (NASDAQ:DRVN) Head to Head Comparison
Driven Brands (NASDAQ:DRVN – Get Free Report) and Autozi Internet Technology (Global) (NASDAQ:AZI – Get Free Report) are both retail/wholesale...